Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Targeted Rhesus immunoglobulin for RhD negative women undergoing an induced abortion: a clinical pilot study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{a06b58d7af2c402e997d772c85ba240c,
title = "Targeted Rhesus immunoglobulin for RhD negative women undergoing an induced abortion: a clinical pilot study",
abstract = "Introduction: The aim of this clinical pilot study was to examine the accuracy of noninvasive fetal RHD genotyping in early pregnancy (8 +0  to 11 +6  weeks) and to clarify whether targeted administration of Rhesus immunoglobulin (RhIg) is possible for women undergoing an induced abortion such that unnecessary injections can be avoided. The study examines the correlation between gestational age and the amount of cell-free fetal DNA in maternal plasma, the fetal fraction of DNA and whether transportation time or body mass index affects these parameters. Material and methods: Fifty-two RhD-negative women undergoing a surgically induced abortion were included. A maternal blood sample was collected prior to the abortion and a tissue sample was collected from the placental part of the abortion material after the intervention. Fetal RhD type was determined by PCR analysis of cell-free fetal DNA extracted from maternal plasma and on DNA from the tissue sample, with the latter providing a reference standard. Copies of RHD/mL were determined on RHD-positive samples and the fetal fraction of DNA was calculated. Results: We demonstrated complete concordance between results from plasma and tissue, with 31 RhD-positive and 21 RhD-negative samples, corresponding to 40{\%} being RhD-negative, specificity 100{\%} [95{\%} confidence interval (CI) 88.8-100] and sensitivity 100{\%} (95{\%} CI 83.9-100). We found no significant correlation between gestational age and the amount or the fraction of cell-free fetal DNA in maternal plasma, nor did we find that transportation time or BMI significantly affected these factors in this setup. Conclusions: Fetal RHD genotyping can be accurately performed from the 8th week of gestation and unnecessary injections of RhIg can be avoided for women undergoing an induced abortion. A larger study is needed to determine a more accurate sensitivity for the analysis early in pregnancy.",
keywords = "cell-free fetal DNA, first trimester, real-time polymerase change reaction, RHD genotyping, rhesus prophylaxis",
author = "Jensen, {Mia Pi S{\o}by} and Merete Damkjaer and Clausen, {Frederik Banch} and Ali, {Haivin Aziz} and Hare, {Kristine Juul} and Dziegiel, {Morten Hanefeld} and J{\o}rgensen, {Finn Stener}",
note = "{\circledC} 2019 Nordic Federation of Societies of Obstetrics and Gynecology.",
year = "2019",
month = "9",
doi = "10.1111/aogs.13606",
language = "English",
volume = "98",
pages = "1164--1171",
journal = "Acta Obstetricia et Gynecologica Scandinavica",
issn = "0001-6349",
publisher = "Informa Healthcare",
number = "9",

}

RIS

TY - JOUR

T1 - Targeted Rhesus immunoglobulin for RhD negative women undergoing an induced abortion

T2 - a clinical pilot study

AU - Jensen, Mia Pi Søby

AU - Damkjaer, Merete

AU - Clausen, Frederik Banch

AU - Ali, Haivin Aziz

AU - Hare, Kristine Juul

AU - Dziegiel, Morten Hanefeld

AU - Jørgensen, Finn Stener

N1 - © 2019 Nordic Federation of Societies of Obstetrics and Gynecology.

PY - 2019/9

Y1 - 2019/9

N2 - Introduction: The aim of this clinical pilot study was to examine the accuracy of noninvasive fetal RHD genotyping in early pregnancy (8 +0  to 11 +6  weeks) and to clarify whether targeted administration of Rhesus immunoglobulin (RhIg) is possible for women undergoing an induced abortion such that unnecessary injections can be avoided. The study examines the correlation between gestational age and the amount of cell-free fetal DNA in maternal plasma, the fetal fraction of DNA and whether transportation time or body mass index affects these parameters. Material and methods: Fifty-two RhD-negative women undergoing a surgically induced abortion were included. A maternal blood sample was collected prior to the abortion and a tissue sample was collected from the placental part of the abortion material after the intervention. Fetal RhD type was determined by PCR analysis of cell-free fetal DNA extracted from maternal plasma and on DNA from the tissue sample, with the latter providing a reference standard. Copies of RHD/mL were determined on RHD-positive samples and the fetal fraction of DNA was calculated. Results: We demonstrated complete concordance between results from plasma and tissue, with 31 RhD-positive and 21 RhD-negative samples, corresponding to 40% being RhD-negative, specificity 100% [95% confidence interval (CI) 88.8-100] and sensitivity 100% (95% CI 83.9-100). We found no significant correlation between gestational age and the amount or the fraction of cell-free fetal DNA in maternal plasma, nor did we find that transportation time or BMI significantly affected these factors in this setup. Conclusions: Fetal RHD genotyping can be accurately performed from the 8th week of gestation and unnecessary injections of RhIg can be avoided for women undergoing an induced abortion. A larger study is needed to determine a more accurate sensitivity for the analysis early in pregnancy.

AB - Introduction: The aim of this clinical pilot study was to examine the accuracy of noninvasive fetal RHD genotyping in early pregnancy (8 +0  to 11 +6  weeks) and to clarify whether targeted administration of Rhesus immunoglobulin (RhIg) is possible for women undergoing an induced abortion such that unnecessary injections can be avoided. The study examines the correlation between gestational age and the amount of cell-free fetal DNA in maternal plasma, the fetal fraction of DNA and whether transportation time or body mass index affects these parameters. Material and methods: Fifty-two RhD-negative women undergoing a surgically induced abortion were included. A maternal blood sample was collected prior to the abortion and a tissue sample was collected from the placental part of the abortion material after the intervention. Fetal RhD type was determined by PCR analysis of cell-free fetal DNA extracted from maternal plasma and on DNA from the tissue sample, with the latter providing a reference standard. Copies of RHD/mL were determined on RHD-positive samples and the fetal fraction of DNA was calculated. Results: We demonstrated complete concordance between results from plasma and tissue, with 31 RhD-positive and 21 RhD-negative samples, corresponding to 40% being RhD-negative, specificity 100% [95% confidence interval (CI) 88.8-100] and sensitivity 100% (95% CI 83.9-100). We found no significant correlation between gestational age and the amount or the fraction of cell-free fetal DNA in maternal plasma, nor did we find that transportation time or BMI significantly affected these factors in this setup. Conclusions: Fetal RHD genotyping can be accurately performed from the 8th week of gestation and unnecessary injections of RhIg can be avoided for women undergoing an induced abortion. A larger study is needed to determine a more accurate sensitivity for the analysis early in pregnancy.

KW - cell-free fetal DNA

KW - first trimester

KW - real-time polymerase change reaction

KW - RHD genotyping

KW - rhesus prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=85063675854&partnerID=8YFLogxK

U2 - 10.1111/aogs.13606

DO - 10.1111/aogs.13606

M3 - Journal article

VL - 98

SP - 1164

EP - 1171

JO - Acta Obstetricia et Gynecologica Scandinavica

JF - Acta Obstetricia et Gynecologica Scandinavica

SN - 0001-6349

IS - 9

ER -

ID: 56813113